QMS Medical Allied Services Completes 100% Acquisition of Saarathi Healthcare for ₹14.225 Crore
QMS Medical Allied Services Ltd has completed the 100% acquisition of Saarathi Healthcare Pvt Ltd for ₹14.225 crore. This move integrates Saarathi's disease management and patient engagement capabilities with QMS MAS's screening and diagnostics services. The company aims to build a comprehensive healthcare platform and has a revenue target of ₹500 crore by FY29.
This is a significant strategic acquisition that consolidates ownership of a key subsidiary, enabling deeper integration and operational synergies. It directly contributes to the company's stated goal of building a comprehensive healthcare services platform and achieving substantial revenue growth.
The acquisition is a strategic step towards building an integrated healthcare platform, which is expected to boost the company's services portfolio and strengthen its market presence. The CMD's positive commentary and the company's ambitious growth targets further support this sentiment.
QMS Medical Allied Services Ltd (QMS MAS) has announced the completion of its 100% acquisition of Saarathi Healthcare Pvt Ltd, making it a wholly owned subsidiary. This strategic move is a significant step in QMS MAS's plan to establish an integrated healthcare services platform that covers patient screening, early diagnosis, disease management, and patient engagement.
The acquisition process began in June 2024 with QMS MAS acquiring a 51% stake in Saarathi Healthcare, which was later increased to 76% in October 2025. With the acquisition of the remaining 24% stake, QMS MAS now holds full ownership.
This complete acquisition is expected to substantially enhance QMS MAS's service offerings and solidify its position in the healthcare services and patient management sector. QMS MAS specializes in patient screening services through its innovative Patient Service Programs (PSP) and the provision of diagnostic medical devices, facilitating access to advanced diagnostic testing and promoting early intervention and preventive healthcare.
Saarathi Healthcare contributes complementary expertise in disease management, early diagnosis, and screening using point-of-care devices, along with disease awareness and access programs across various therapies. Its operational model integrates digital tools with direct patient engagement, supporting healthcare programs throughout the patient's journey.
Mr. Mahesh Makhija, CMD of QMS Medical Allied Services Ltd, stated, "The 100% acquisition of Saarathi Healthcare marks an important milestone in our journey towards building a comprehensive and integrated healthcare services platform. By bringing together QMS MAS’s strengths in patient screening and diagnostics with Saarathi’s capabilities in disease management and patient engagement, we aim to provide a more connected continuum of care. Full ownership will enable us to drive deeper integration, strengthen operational synergies and create greater value for patients, healthcare partners and stakeholders."
QMS MAS acquired the remaining 24% equity stake, comprising 1,98,000 shares, for a cash consideration of ₹14.225 crore. This acquisition further reinforces QMS MAS's strategy to build an integrated healthcare platform encompassing early detection, patient screening, disease management, and sustained patient engagement.
This development follows a period of rapid growth for QMS MAS, including its migration to the NSE Mainboard in June 2026 and a recent five-year exclusive agreement with Germany-based HEINE Optotechnik for marketing and distributing their primary diagnostic instruments in India. With a scalable product vertical and a growing healthcare services portfolio as its core growth drivers, QMS MAS has set an ambitious revenue target of exceeding ₹500 crore by FY29.
What to do with a filing like this
QMS Medical Allied Services Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by QMS Medical Allied Services Limited. Read the original for the full detail.